• In early May 2026, Revolution Medicines reported a first-quarter net loss of US$453.82 million, with basic loss per share from continuing operations of US$2.29, wider than a year earlier, while the FDA issued a “safe to proceed” letter enabling expanded access to its investigational pancreatic cancer drug, daraxonrasib.
• This combination of heavier quarterly losses and regulatory progress for daraxonrasib, already supported by Breakthrough Therapy and Orphan Drug designations, sharpened the focus on how Revolution Medicines balances cash-intensive development with advancing treatments for hard-to-treat pancreatic cancer.
• Next, we’ll examine how the FDA’s expanded access approval for daraxonrasib reshapes Revolution Medicines’ investment narrative around its RAS-focused pipeline.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Revolution Medicines Investment Narrative Recap

To own Revolution Medicines, you need to believe that its RAS focused oncology pipeline, led by daraxonrasib, can ultimately justify years of heavy, pre revenue spending. The wider first quarter net loss of US$453.82 million underlines how dependent the story is on converting late stage trials into approvals, while the FDA’s expanded access green light for daraxonrasib reinforces that the key near term catalyst and risk center on this lead pancreatic cancer program.

The expanded access decision is especially relevant because it follows positive Phase 3 RASolute 302 data and the company’s plan to submit a new drug application for daraxonrasib. Together, these steps could influence how quickly daraxonrasib might move from an investigational therapy into a commercial product, which in turn sits at the heart of how investors weigh the short term cash burn against longer term potential returns from Revolution Medicines’ RAS(ON) portfolio.

Yet, while the headlines are encouraging, investors should still pay close attention to how prolonged high operating expenses and ongoing losses could affect...

Revolution Medicines' narrative projects $1.0 billion revenue and $148.6 million earnings by 2029. This implies earnings improving by about $1.2 billion from -$1.1 billion today.

Uncover how Revolution Medicines' forecasts yield a $133.70 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were modeling about US$2.1 billion of revenue and US$424 million of earnings by 2029, which is far more upbeat than consensus and assumes smooth execution despite trial timing and operational risks that could easily shift after developments like the expanded access decision.

Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth 37% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Revolution Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Revolution Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revolution Medicines' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.